A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia

To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.

To evaluate the effect of multiple subcutaneous (SC) doses of benralizumab (MEDI 563) on the rate of moderate-to-severe annualized incidence rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with moderate-to-severe COPD who exhibit eosinophilia (greater than or equal to [>=] 3.0 percent [%] sputum eosinophilia in the previous 12 months or at Screening) in sputum compared to placebo.

Inclusion Criteria:

• Subjects aged 40-85 years at the time of Screening
• Written informed consent obtained from the subject prior to performing any protocol related procedures
• Documented history of 1 or more Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)
• Current smoker or ex-smoker with a tobacco history of greater than or equal to (>=) 10 pack-years
• Adequate contraception from screening through end of trial
• Able to read and write.

Exclusion Criteria:

• Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
• Pregnant, breastfeeding, or lactating women
• Known history of allergy or reaction to any component of the investigational product formulation
• History of anaphylaxis to any other biologic therapy
• Donation or transfusion of blood, plasma or platelets within the past 3 months prior to Screening
• Other significant pulmonary disease which in the opinion of the investigator or medical monitor, might compromise the interpretation of the study
• Fever greater than (>) 37.0 degree Centigrade (98.6 degree Fahrenheit) at Screening
• Receipt of any novel investigational medicinal product within 3 months before the first dose of investigational product in this study and through the end of the study
• Seropositive for hepatitis A, hepatitis B surface antigen, hepatitis C, or human immunodeficiency virus 1or 2 (HIV-1 or HIV 2)
• History of alcohol or drug abuse within the past year that required treatment that the investigator felt or medical monitor felt would compromise the study data interpretation
• Past or current malignancy within the past 5 years except adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than 1 year prior to Screening
• Subjects participating in, or scheduled for, an intensive COPD rehabilitation program (subjects who are in the maintenance phase of a rehabilitation program are eligible to take part)
• Current diagnosis of asthma according to Global Initiative for Asthma guidelines
• Previous treatment with MEDI-563.